{"id":"NCT02842853","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","officialTitle":"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-15","primaryCompletion":"2017-02-28","completion":"2017-02-28","firstPosted":"2016-07-25","resultsPosted":"2020-03-09","lastUpdate":"2022-04-05"},"enrollment":3344,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Meningitis","Meningococcal Meningitis","Meningococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine","otherNames":["MenACYW conjugate vaccine"]},{"type":"BIOLOGICAL","name":"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine","otherNames":["Menactra®"]}],"arms":[{"label":"MenACYW Conjugate Vaccine Lot 1","type":"EXPERIMENTAL"},{"label":"MenACYW Conjugate Vaccine Lot 2","type":"EXPERIMENTAL"},{"label":"MenACYW Conjugate Vaccine Lot 3","type":"EXPERIMENTAL"},{"label":"Menactra®","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study was to evaluate immune lot consistency of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine and the immune non-inferiority compared to the licensed vaccine Menactra®, and describe the safety and additional immunogenicity of these study vaccines in adolescents and adults 10 to 55 years of age in the United States (US).\n\nPrimary Objectives:\n\n* To demonstrate the immune lot consistency of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine with respect to serum bactericidal assay using human complement (hSBA) geometric mean titers (GMTs).\n* To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra®.\n\nSecondary Objective:\n\n* To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra® in the adult population (18 to 55 years old).\n* To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra® in the adolescent population (10 to 17 years old).\n* To compare the hSBA vaccine seroresponses of meningococcal serogroups A, C, Y, and W for each of 3 lots of MenACYW Conjugate vaccine 30 days (+14 days) after vaccination.\n* To compare the hSBA antibody GMTs of meningococcal serogroups A, C, Y, and W following the administration of MenACYW Conjugate vaccine to those observed following the administration of Menactra®.\n\nObservational Objectives:\n\n* To describe the safety profile of MenACYW Conjugate vaccine and that of the licensed Menactra®.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of Meningococcal Serogroups A, C, Y, And W Antibodies Following Vaccination With 3 Lots of MenACYW Conjugate Vaccine","timeFrame":"Day 30 (post-vaccination)","effectByArm":[{"arm":"MenACYW Conjugate Vaccine Lot 1","deltaMin":84.9,"sd":null},{"arm":"MenACYW Conjugate Vaccine Lot 2","deltaMin":96.5,"sd":null},{"arm":"MenACYW Conjugate Vaccine Lot 3","deltaMin":97.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":19},"locations":{"siteCount":89,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":895},"commonTop":["Injection site pain","Myalgia","Headache","Malaise","Injection site erythema"]}}